ARCHIVES

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

This article is from The Cancer Letter archive.

Vol. 29 No. 46 | December 12, 2003

Download PDF Visit The Full Archive

Related Articles

Guideline Revisions or Outstanding Investigator Grant Still Controversial

December 9, 1983

IOM Report Urges DOD, VA, Congress To End Tobacco Use In Military.

July 10, 2009

FDA Approves Aranesp For Chemo-Induced Anemia

August 30, 2002

Waksal Pleads Guilty To Securities Fraud

October 18, 2002

NCI Advisory Group, Other Cancer Meetings

August 19, 1983

Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.

March 2, 2001